Margarida Azevedo, MSc,  —

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Articles by Margarida Azevedo

ALS Association Grants $1.5M to Researcher Robert G. Miller

The ALS Association has recently awarded a $1.5 million grant to investigator Robert G. Miller, MD, to be invested in the study of a potential treatment for amyotrophic lateral sclerosis (ALS), called NP001. Dr. Miller is studying Neuraltus Pharmaceuticals’ investigational therapy which will now enter a phase 2 clinical trial.

Patient Dares ALS Association to Set 2021 For Cure Goal

Chris Rosati, who was diagnosed with amyotrophic lateral sclerosis (ALS) in November 2010, challenged the ALS Association to publicly declare that a cure for the disease will be found in the next six years. In an emotional video addressed to the association’s CEO Barbara Newhouse, Mr. Rosati explained…